Levodopa/Carbidopa/Entacapone Viatris

Levodopa/Carbidopa/Entacapone, the active ingredient in Levodopa/Carbidopa/Entacapone Viatris, is a combination (dopamine precursor, dopa decarboxylase inhibitor, COMT inhibitor) presented as an oral tablet for oral use. It treats Parkinson's disease in adults by increasing central dopamine availability.

GNH USA supplies Levodopa/Carbidopa/Entacapone Viatris as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is used in the management of Parkinson's disease and related motor fluctuations.

- Parkinson's disease: improves overall motor symptoms and daily functioning. - Wearing‑off phenomenon: reduces off‑periods and stabilises response to levodopa. - Advanced Parkinson's disease: enhances and prolongs the therapeutic effect of levodopa therapy.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Insomnia - Dyskinesia

Serious or Rare Side Effects: - Severe hypotension or syncope - Neuroleptic malignant syndrome - Significant liver dysfunction - Agranulocytosis or severe neutropenia - Anaphylactic or severe allergic reactions - Emergence of suicidal thoughts or behaviors

Before initiating therapy, clinicians should consider several safety measures.

- Blood pressure monitoring: watch for orthostatic changes. - Liver function assessment: evaluate baseline hepatic enzymes. - Psychiatric evaluation: screen for depression or psychosis. - Renal impairment adjustment: modify dose if necessary. - Hypersensitivity check: avoid in patients with known allergy to any component. - Store at ambient temperature: keep in original container, protect from moisture.

Levodopa/Carbidopa/Entacapone can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO‑B inhibitors (e.g., selegiline): risk of hypertensive crisis. - Non‑selective MAO inhibitors: may cause severe hypertension. - Anticholinergic agents (e.g., benztropine): increase anticholinergic burden. - Certain antihypertensives (e.g., clonidine): may precipitate profound hypotension. - Iron or calcium supplements: reduce levodopa absorption.

Moderate Interactions (Monitor Closely): - SSRIs (e.g., sertraline): potential serotonin syndrome. - Antipsychotics (e.g., haloperidol): may diminish dopaminergic effect. - Diuretics: influence blood pressure stability. - NSAIDs: increase risk of gastrointestinal bleeding. - Vitamin B6 (pyridoxine): may antagonise levodopa efficacy.